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Abstract
Background: Parents commonly ask about food allergy tests, to find a cause for their 
child's eczema, yet the value of routine testing is uncertain.
Objective: To determine whether a clinical trial comparing test-guided dietary advice 
versus usual care, for the management of eczema, is feasible.
Methods: Children (>3 months and <5 years) with mild-to-severe eczema, recruited 
via primary care, were individually randomized (1:1) to intervention or usual care. 
Intervention participants underwent structured allergy history and skin prick tests 
(SPT) with dietary advice for cow's milk, hen's egg, wheat, peanut, cashew and cod-
fish. All participants were followed up for 24 weeks. A sample of doctors and parents 
was interviewed. Registration ISRCTN15397185.
Results: From 1059 invitation letters sent to carers of potentially eligible children, 84 
were randomized (42 per group) with mean age of 32.4 months (SD 13.9) and POEM of 
8.7 (4.8). Of the 42, 6 (14%) intervention participants were advised to exclude one or 
more foods, most commonly egg, peanut or milk. By participant, 1/6 had an oral food 
challenge (negative); 3/6 were told to exclude until review in allergy clinic; and 6/6 
advised a home dietary trial (exclusion and reintroduction of food over 4–6 weeks) 
– with 1/6 partially completing it. Participant retention (four withdrawals) and data 
completeness (74%–100%) were acceptable and contamination low (two usual care 
participants had allergy tests). There were three minor SPT-related adverse events. 
During follow-up, 12 intervention and 8 usual care participants had minor, unrelated 
adverse events plus one unrelated hospital admission.
Conclusions: It is possible to recruit, randomize and retain children with eczema from 
primary care into a trial of food allergy screening and to collect the outcomes of inter-
est. Changes to recruitment and inclusion criteria are needed in a definitive trial, to 
ensure inclusion of younger children from more diverse backgrounds.
2  |    RIDD et al.
1  |  INTRODUC TION
One in five preschool children in the United Kingdom have eczema, 
the clinical phenotype of atopic eczema/dermatitis.1 More than half 
develop symptoms by 1 year of age and almost all by 5 years of age.2 
Eczema is associated with food allergy, and allergic reactions to dif-
ferent foods may cause eczema symptoms, either as part of an IgE or 
non-IgE-mediated reaction.3
A common perception among parents and carers (hereafter 
parents) of children with eczema is that all symptoms are caused 
by food allergies.4,5 They often seek information online but unfor-
tunately much of the advice is erroneous and some dangerous.6,7 
Consequently, many parents restrict their child's diets and request 
allergy testing to guide dietary decision-making.7,8
Nwaru et al.9 reviewed the prevalence of the most common 
foods to cause IgE-mediated allergic reactions in children: cow's 
milk, egg, wheat, soy, peanut, tree nuts, fish and shellfish. They 
found an up to 15-fold difference between self-reported and chal-
lenge-verified prevalence of food allergy. Lifetime self-reported 
point prevalence is highest for cow's milk allergy (2.3%) and low-
est for fish allergy (0.6%). Based on objective food challenges, 
the prevalence is highest for cow's milk allergy (0.6%) and lowest 
for wheat and shellfish allergy (both 0.1%). In general, the prev-
alence of cow's milk allergy and egg allergy is higher in younger 
age groups than older age groups, while the prevalence of peanut 
allergy, tree nut allergy and fish allergy is higher in the older age 
groups. They found insufficient data to compare the estimates of 
soy and wheat allergy between the age groups. The discrepancy 
between self-reported and objective figures, particularly for milk, 
soy and wheat, may in part be due to non-IgE-mediated food al-
lergy but also through over-reporting of symptoms.10 Food allergy 
is more common in children with eczema, however. Tsakok et al.11 
report that up to 53%–66% of people with eczema are food sen-
sitized, and 15%–81% have challenge-proven food allergy. Earlier 
onset, persistent and more severe disease is associated with in-
creased risk of food allergy.3
It remains unclear, however, whether test-guided dietary deci-
sions improve eczema symptoms, or negatively affect children by 
unnecessarily reducing dietary choices12,13 and distract from the use 
of conventional treatments.14 Furthermore, there is evidence that 
children with eczema may benefit from early introduction of some 
allergenic foods. Introducing peanut and cooked hen's egg into the 
infant diet, as part of complementary feeding, may reduce the risk 
of peanut or egg allergy.15 It is uncertain whether excluding these or 
other foods to which infants are sensitized but tolerant may increase 
the risk of food allergy developing, and if this is the case, how long 
after allergen exclusion this is likely to occur.
Ierodiakonou et al.16 found no consistent association between 
timing of allergenic food introduction and risk of eczema from either 
intervention or observational studies. One trial of infants with estab-
lished eczema suggested dietary exclusion of eggs may be useful in 
children with positive allergy testing for egg. However, the trial was 
small (55 participants), in a specific population (paediatric dermatology 
clinic), with short follow-up (4 weeks) and no patient-reported out-
comes.17 Better designed and conducted trials are needed to deter-
mine whether test-guided dietary management is worthwhile in the 
management of eczema.18,19 In the Trial of Eczema allergy Screening 
Tests (TEST) study, we aimed to find out whether conducting a trial 
comparing food allergy testing and dietary advice versus usual care, 
for the management of childhood eczema in primary care, is feasible.
2  |  METHODS
2.1  |  Design
The protocol for this trial is published elsewhere,20 but in brief TEST 
was a single-centre, two-group, individually randomized, feasibil-
ity randomized controlled trial (RCT), with economic scoping and a 
nested qualitative study.
2.2  |  Participant recruitment and eligibility criteria
Between September 2018 and February 2019, participants were re-
cruited from primary care centres located in, and surrounding, the 
city of Bristol, England. Eligible participants were children aged over 
3 months and <5 years with mild or worse eczema, as defined by a 
Patient Oriented Eczema Measure (POEM)21 score of greater than 
two (scale 0–28, with a higher score equating worse eczema).22 We 
excluded children with medically diagnosed food allergy, awaiting 
referral/investigations for possible food allergy or who had previous 
investigations for food allergy.
Potentially eligible children were identified from a search of 
their primary care electronic medical records. Family Practitioners 
(FPs) were asked to exclude children who would be ineligible prior to 
sending their parent an invitation letter. Parents could also self-refer 
their child into the study opportunistically.
2.3  |  Procedure
Interested parents attended a baseline appointment at their pri-
mary care centre, where consent was received, data collected 
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and randomization undertaken by a Clinical Studies Officer. 
Participants were randomized 1:1 to either the intervention or 
usual care, using a web-based system stratified by age and severity 
of eczema. The allocation sequence was concealed, and randomi-
zation was not done until all baseline measurements were com-
pleted. Participants, parents and their doctors were not masked 
to the allocation.
Participants in the intervention group underwent a structured 
allergy history, skin prick tests (SPTs) and were given dietary advice 
regarding six foods: cow's milk, hen's eggs, peanut, cashew, codfish 
and wheat. The structured allergy history was administered by the 
Clinical Studies Officer, which asked about relevant symptoms (skin, 
respiratory and gastrointestinal) and timing of onset in relation to 
ingestion of the study foods. The same researcher performed the 
SPTs using commercial extracts of the foods, along with positive 
(1.0% histamine) and negative (0.9% saline) controls, following stan-
dard procedure.23 The findings of the structured allergy history 
and SPTs were interpreted by following an algorithm to determine 
what advice or further action was recommended. All participants’ 
results were reviewed by an allergy panel (MR, RB, DM and/or LW) 
and advice on food ingestion/avoidance relayed to the participant's 
parent by the Clinical Studies Officer. Children with possible IgE-
mediated symptoms underwent an open food challenge which was 
supervised by DM at the Bristol Royal Children's Hospital, using a 
modified Practical Allergy (PRACTALL) dosing schedule and criteria 
for interpretation of challenge outcome.24 For children with possi-
ble delayed allergy symptoms, families were advised to exclude the 
possible allergen from their diet over a 2- to 4-week period and then 
reintroduce.
Participants allocated to usual care did not receive any additional 
assessments or tests as part of the study, but their treating clinicians 
could independently request these if deemed clinically indicated 
during the follow-up period.
Participants were followed up for 24 weeks. Parents were asked 
to complete questionnaires four-weekly and attend a face-to-face 
assessment of their child's skin at 24 weeks.
2.4  |  Outcome measures
The main outcome of interest was the feasibility of conducting 
the trial and collecting the required data. As recommended by the 
core outcome group for eczema (HOME),25 the feasibility of col-
lecting data on symptoms, signs and quality of life was assessed. 
The following instruments were used:
1. Symptoms and long-term control – Patient Oriented Eczema 
Measure (POEM)21
2. Clinical signs – Eczema Area Severity Index (EASI)26
3. Quality of life – Atopic Dermatitis Quality of Life (ADQoL),27 
Infant Dermatitis Quality of Life (IDQoL)28 and Child Health 
Utility 9D (CHU9D)29
We determined that a sample size of 80 participants was suffi-
cient to inform the chosen outcomes.
2.5  |  Analysis
Trial data were analysed descriptively, using Stata (version 15.1). 
Scale and quality of life scores were calculated following recom-
mended conventions. Descriptive statistics were used to describe 
participant recruitment, retention, adherence and contamination.
2.6  |  Health economics scoping
Healthcare (hospital visits and stays) and personal (over-the-counter 
medications, personal expenses, private/alternative treatments, 
travel, time off work/school) resource use were collected via the 
parent-completed diaries. All primary care consultations and pre-
scribed medications were extracted from electronic medical records: 
eczema and/or food allergy-related consultations and prescribed 
medications were independently identified from the records by two 
clinicians (MJR and MS) and agreement compared.
2.7  |  Nested qualitative study
We audio-recorded semi-structured interviews with 11 doctors 
and 21 parents, employing a flexible topic guide. Participants were 
purposively sampled: parents from both intervention and usual care 
groups, of children with a range of eczema severity, with varied so-
cio-economic status, different lengths of time in the trial and test re-
sults; doctors from a range of practices, with differing lengths of time 
in the trial and attitudes to allergy testing. We stopped interview-
ing when we judged that we had achieved sufficient “information 
power”.30 Interviews were transcribed, anonymized and analysed 
thematically using both inductive and deductive coding,31,32 aided 
by NVivo 10.
We present data relevant to the feasibility of the trial here, while 
more detailed findings on participants’views on food allergy testing 
in eczema are published separately.33
2.8  |  Public and patient involvement
The role of food allergy testing was identified by parents, patients 
and clinicians as a priority in a James Lind Alliance eczema research 
priority-setting exercise.34 Two parents of children with eczema and 
food allergies regularly attended trial management meetings and com-
mented on study materials and participant newsletters. We also had 
parent representation on the trial steering/data monitoring committee.
We held three group meetings with parents of children with ec-
zema over the course of the study, where feedback on the design, 
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delivery and findings of the trial were discussed. We also undertook 
three engagement events at the end of the trial with stakeholders 
and the general public.
Ethical approval
The study was reviewed by the Health Research Authority and 
given a favourable opinion by the NHS REC (West Midlands – South 
Birmingham Research Ethics Committee, Reference Number 18/
WM/0124).
3  |  RESULTS
3.1  |  Participant recruitment and characteristics
Participants were recruited between September 2018 and February 
2019 from 17 primary care centres. FPs were supportive of hosting 
the trial in their practice:
I think what attracted us to this trial was potentially 
having something else to be able to advise parents. 
(FP 11)
The flow of the participants through the trial is shown in the 
CONSORT diagram (Figure 1). A total of 1276 potentially eligible chil-
dren were identified on searches of electronic medical records but 217 
were excluded by FPs, the most common reason (46%, 99/217) being 
diagnosed or suspected food allergy. Some doctors experienced diffi-
culties applying some of the inclusion/exclusion criteria pre-invitation, 
for example:
It’s difficult [identifying when a child no longer has ec-
zema] because all we're going to get is an EMIS [elec-
tronic medical record] code saying eczema, we're not 
going to get one saying ‘no longer has eczema’ and 
obviously because it sort of flares up and dies down 
doesn't it so I don't think - I certainly never coded ‘no 
longer has eczema’ for anything. So, I don't think re-
ally we'd be able to pick that up. 
(FP 11)
Replies were received from 203/1059 (19%) invitation letters 
with four additional opportunistic expressions of interest. Of these, 
143 children were potentially eligible and 84 were randomized (42 
into each group), 82 of these responding to the postal invitation 
and two self-referrals. The mains reasons for non-randomization 
were (Figure 1) participant declined/uncontactable (31/143, 22%) 
and baseline visits not booked/conducted (24/143, 17%).
Scheduling and conducting baseline appointments were often 
challenging for multiple reasons: requirements relating to the 
primary care centre (availability of a suitable room and doctor on-
site in case of an emergency), participant (availability of working par-
ent and participant, “well child” including no recent antihistamine 
use) and availability of Clinical Studies Officer.
The baseline characteristics of the children and their consenting 
parent are shown in Table 1. Children's mean age was 32.4 months 
(SD 13.9), with 48% female (40/84) and 77% white (65/84). 70% 
(59/84) of participants met the UK diagnostic criteria for atopic der-
matitis35 with disease of mostly mild-moderate severity (POEM 8.7, 
SD 4.8; EASI 2.0, IQR 1.0, 4.8). The mother most commonly gave 
consent (78/84, 93%) and most consenting parents (48/84, 57%) 
were educated to degree level or equivalent.
Comparing what data were available on children who were in-
vited with those who took part, there did not appear to be a differ-
ence in respect of age or gender, but self-reported disease severity 
was worse in potentially eligible/randomized children (Table S1).
3.2  |  Intervention delivery, acceptability and 
advice given
All 42 participants randomized to the intervention group had com-
plete allergy history and SPTs. However, the duration of baseline 
appointments for intervention participants (up to 90 min, com-
pared with ~45 min for usual care, of which ~30 min for allergy 
history and skin prick testing) was sometimes trying for the young 
child.
By taking part in the trial, parents consented to randomization, 
yet some allocated to the usual care group expressed relief at not 
having to undergo skin prick testing:
I was quite glad … he didn't have to do allergy testing 
… once I saw the fact that he wasn't that happy about 
being probed and prodded. I thought yeah, probably 
better off not having to do it. 
(Parent 7)
The majority (36/42, 85.7%) of intervention participants reported 
no allergy symptoms and had negative SPTs. In interviews, most ac-
cepted the results, finding them useful for ruling out the possibility of 
food allergy or reassuring them about their current practice with their 
children:
We had a negative result … but it definitely made 
a difference in terms of ok put your mind to rest … 
made us a bit more relaxed … And also, maybe more 
feeling of being in control. 
(Parent 14)
However, some felt frustrated, still not knowing the cause of their 
child's eczema or how best to manage it, or doubted the veracity or 
comprehensiveness of the tests:
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F I G U R E  1  CONSORT – participant recruitment and follow-up
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I still don't know if he has an allergy to anything that 
wasn't tested, ‘cos they only test for certain ones’. 
(Parent 16)
Six of the intervention participants had a history or SPTs result 
suggestive of possible food allergy. Three of these participants were 
advised regarding one food, one regarding two foods, one regard-
ing three foods and one regarding four foods (Figure 2). The foods 
most commonly raising concern were egg (four participants), pea-
nut (three participants) and milk (three participants). Dietary advice 
given to each of these participants: all six were asked to exclude 
one food at home; one had an oral food challenge to peanut, which 
was negative; and three were referred to the local allergy clinic for 
follow-up .
3.3  |  Participant follow-up
Retention in the study was good with only four participants with-
drawing (Figure 1 – three from usual care; one from intervention). 
Reasons for withdrawal (not mutually exclusive) were not hav-
ing enough time (four participants); my child's eczema has im-
proved (one participant); the study is not helpful for my child (one 
participant).
Completion of data items across the seven time-points (baseline 
through to week 24) was good (Table 2), varying from 74% (“Diet of 
child” most poorly completed question items) to 100%.
3.4  |  Adherence to dietary advice and 
contamination
Except for peanut consumption in intervention participants 
(which was lower at 24 weeks), parent-reported consumption of 
the six foods were similar among both usual care participants and 
“test negative” intervention participants at baseline and week 24 
(Table S2).
Adherence in the six “test positive” intervention participants was 
mixed. Regarding reported consumption of high-risk food(s) (that 
parents had been advised to exclude because of the need for as-
sessment in allergy clinic or with an oral food challenge), adherence 
was 81% (29/36 person-weeks of available data). Regarding home di-
etary trial of low-risk foods, only 1/6 participant reported that they 
tried excluding (cow's milk) but did not reintroduce it because of a 
perceived reduction in eczema symptoms.
There were no reports of participants in the intervention group 
whose tests were negative seeking allergy testing after the baseline ap-
pointment. In the usual care group, two participants saw an allergy spe-
cialist following the baseline appointment and had allergy testing: one 
due to a possible food reaction and one private referral at the request 
of the parent.
3.5  |  Outcomes and adverse events
The main outcomes collected were similar between the two 
groups over the 24-week follow-up (Table 3). There were five 
minor adverse events in the intervention group at baseline after 




Mean age in 
months (SD)
42 33.5 (15.2) 42 31.4 (12.7)
Number (%) 
female
42 21 (50%) 42 19 (45%)
Number (%) white 42 34 (81%) 42 31 (74%)




Not at all 39 (93%) 40 (95%)
Partially 3 (7%) 2 (5%)
Fully 0 (0%) 0 (0%)
Number (%) 
formula-fed









42 9.0 (5.2) 42 8.4 (4.5)
Median EASI 
(IQR)




42 0.841 (0.744, 
0.841)




42 3 (2, 6) 42 4 (2, 5)
Median CHU9D 
(IQR)
42 0.951 (0.915, 
0.979)
42 0.960 (0.908, 
1.000)
Parent/legal guardian
Mean age (SD) in 
years (SD)
42 34.7 (5.6) 42 34.6 (5.5)
Median (IQR) 
GAD−7 score
42 4 (0, 10) 42 3 (1, 7)
POEM (Patient Oriented Eczema Measure) range 0 to 28, high =worse 
eczema; EASI (Eczema Area Severity Index) min 0, max 72, high =worse 
eczema; ADQOL (Atopic Dermatitis Quality of Life), range 0 (as bad as 
being dead) to 1 (perfect health); IDQOL (Infant Dermatitis Quality of 
Life), range 0 to 30, high =worse quality of life; CHU9D (ChildHealth 
Utility 9D), range 0 (as bad as being dead) to 1 (perfect health); GAD-7 
(General Anxiety Disorder, seven-item): range 0 to 21, high =worse 
anxiety.
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SPT (three related – localized redness, flushing or swelling of skin; 
and two unrelated – tiredness), which did not require any treat-
ment. During follow-up, 12 children in the intervention and 8 in 
usual care groups had unrelated adverse events, mostly minor 
(Table S3) with one unrelated hospital admission for asthma by a 
child in the intervention group.
3.6  |  Health economics scoping
Diary resource use data were generally well-completed. For exam-
ple, data completion for personal expenses ranged from 74% to 82%. 
While for some resources many parents reported usage, for example 
45 parents reported buying over-the-counter medications, for other 
F I G U R E  2  Advice given to intervention participants, by food and outcome
TA B L E  2  Completeness of data by time point
Number (%) completed
Week 0 4 8 12 16 20 24
Questionnaires 
returned; n (%)
POEM 84 (100%) 72 (86%) 71 (85%) 69 (82%) 70 (83%) 66 (79%) 67 (80%)
Eczema bother 84 (100%) 72 (86%) 71 (85%) 69 (82%) 70 (83%) 66 (79%) 66 (79%)
Itch intensity 84 (100%) 72 (86%) 71 (85%) 69 (82%) 70 (83%) 66 (79%) 66 (79%)
Parental global 
assessment
84 (100%) 72 (86%) 71 (85%) 68 (81%) 70 (83%) 66 (79%) 67 (80%)
EASI 83 (99%) - - - - - 75 (90%)
Diet of child 82 (98%) 67 (80%) 69 (82%) 62 (74%) 64 (76%) 62 (74%) 63 (75%)
IDQOL 83 (99%) - 70 (83%) - - - 66 (79%)
CHU9D 84 (100%) - 68 (81%) - - - 63 (75%)
ADQoL 84 (100%) - 69 (82%) - - - 63 (75%)
GAD−7 84 (100%) - - - - - 66 (79%)
Exit questionnaire - - - - - - 71 (85%)
EMR review - - - - - - 84 (100%)
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resources, most parents did not report any use. Between 3% and 7% 
of parents reported travel costs, and 4% of parents reported private 
or alternative treatment use. Agreement between two clinicians on 
electronic medical record data about participant eczema/food al-
lergy-related consultations and prescribed medications was high (be-
tween 78% and 85%).
Completion of the ADQoL and CHU9D was similar across mea-
sures and treatment groups (Table 3). Missing answers were mainly 
due to whole measure not having been completed.
4  |  DISCUSSION
4.1  |  Summary
We were able to recruit participants via, and deliver our interven-
tion in, primary care centres, exceeding our target sample size within 
the planned 6-month recruitment period. Most participants were re-
cruited via postal invitation, and while the logistics of the baseline 
visit were sometimes challenging (scheduling a time to conduct and 
appointment length), we found that the allergy testing component 
was acceptable to FPs and parents, with only minor adverse events. 
The lower than expected number of children in the intervention 
group (6/42, 14.3%) with “positive” tests reflects the population 
of children recruited to the study (mean age 32.4 months; with the 
most common reason for FPs excluding potentially eligible children 
being diagnosed or suspected food allergy). Participant retention, 
data completeness, reported adherence and contamination over the 
24-week follow-up period were good overall. However, adherence 
to home dietary trials advice was poor, with only one of six partici-
pants partially excluding (but not reintroducing) one food. We have 
demonstrated that it is feasible to collect patient-level data on NHS 
and personal resource use and have identified areas where data col-
lection can be optimized, which may reduce parent-burden (removal 
or refinement of question items) and improve data quality.
4.2  |  Strengths and limitations
Our trial was well conducted and included a nested qualita-
tive study, findings of which support the quantitative results. 
Specifically, FPs supported the need for the trial and parents were 
generally satisfied with their allocation and, in the intervention 
group, test results. However, FPs identified problems in “pre-
screening” potentially eligible children against eligibility criteria at 
the mail-out stage and not all intervention parents were reassured 
by the SPT findings. In the design and delivery of the study, we 
built on learning from other eczema trials,36–38 benefitted from 
a multidisciplinary team (FPs, nurses, allergy specialists, dietitian, 
methodologists) and good patient and public involvement. We 
have been careful throughout to focus on the data that informs 
the feasibility of the proposed main trial, rather than clinical find-
ings themselves.
The main limitation relates to the generalizability of our findings. 
The mean age of participants was higher than expected and con-
sequently breastfeeding rates at time of enrolment were low (none 
fully and two partially breastfeeding at baseline). This means that we 
were unable to explore a prior concern that advice to exclude foods 
may discourage breastfeeding. Parents were also highly educated 
(57% degree or equivalent).
While the number of “test positive” intervention participants 
was lower than expected, half of these participants had issues with 
two or more foods. We have limited insight into why these children 
had not been identified before but may include factors such as lim-
ited access to formal assessment of food allergy; and difficulties 
attributing ingestion of foods to delayed symptoms (non-IgE-medi-
ated allergies). In the nested qualitative study,33 the one “positive” 
intervention participant we spoke to had suspected a food allergy 
but despite seeking advice from their FP had not been investigated 
further and had experimented with dietary changes without profes-
sional guidance. Therefore, our understanding of how a positive test 
result affects parents and future management of the child's condi-
tion is also limited.
Our data on adherence to dietary advice are limited in three re-
spects. First, only 6/42 participants were asked to exclude one or 
more foods. Second, our follow-up questionnaires on food consump-
tion did not distinguish between baked/cooked milk/egg. Lastly, we 
also do not have any qualitative data to help us understand the ac-
ceptability, or otherwise, of home dietary trials.
This was a feasibility study so was therefore not designed to de-
tect difference between the two groups in terms of eczema severity 
or other outcomes.
TA B L E  3  Outcome measure scores at baseline and follow-up
Intervention Usual care
n Baseline (week 0) n Follow-up (week 24) n Baseline (week 0) n
Follow-up (week 
24)
Mean POEM (SD) 42 9.0 (5.2) 31 7.9 (6.0) 42 8.4 (4.5) 36 7.5 (5.7)
Median EASI (IQR) 41 1.7 (0.7, 4.8) 39 1.4 (0.2, 3.1) 42 2.1 (1.1, 4.0) 36 2.7 (0.6, 4.25)
Median GAD−7 (IQR) 42 3.5 (0, 10) 31 1 (0, 4) 42 3 (1, 7) 35 2 (0, 4)
Mean ADQoL (IQR) 42 0.841 (0.744, 0.841) 29 0.841 (0.756, 0.841) 42 0.841 (0.744, 0.841) 34 0.841 (0.756, 0.841)
Median IDQoL (IQR) 42 3 (2, 6) 40 2 (1, 3) 42 4 (2, 5) 40 3 (1.5, 5)
Median CHU9D (IQR) 42 0.951 (0.915, 0.979) 29 0.946 (0.898, 1.000) 42 0.960 (0.908, 1.000) 34 0.926 (0.861, 1.000)
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4.3  |  Literature
As far as we are aware, this is the first study of its kind to be con-
ducted in primary care. We drew on learning from the BEEP study,39 
which also successfully delivered SPTs to young children in a com-
munity setting. The response rates observed from the mail-out 
invitation (203/1059, 19.2%) is similar to38,40 and the proportion 
meeting the UK diagnostic criteria for atopic dermatitis (70.0%) is 
higher than41 other trials of children with eczema in primary care.
Prior research has established that many parents are interested in 
dietary changes and allergy testing as a potential “cure” for their child's 
eczema and are frustrated when this is not discussed or is dismissed by 
their doctor.4,5 Lay understanding of the limitations of blood and skin 
prick food allergy tests and non-specialist's confidence in interpreting 
results are further barriers to the appropriate care of these children.42 
Parental belief that eczema is due to a food allergy can be a barrier 
to effective treatment, lead to unnecessary and potentially harmful 
dietary restrictions and is a source of parental frustration with health-
care professionals.4,5,8 Previous research has also highlighted paren-
tal concern about environmental as well as food allergens43 although 
these are usually more of an issue in older children with atopy.44
Of 1276 potentially eligible children, 99 (7.8%) were excluded 
because of diagnosed or suspected food allergy; and 6/42 (14.3%) 
of intervention participants had possible/probable allergy to one or 
more foods. This compares with published estimates of 15%–36% 
of children with eczema and 6% of the general population.45 These 
disparities probably reflect differences in the populations studied 
and how allergy is defined. We assessed for possible allergies to six 
of the most common food allergens.46 As expected, egg, peanut and 
milk were most frequently associated with positive findings.47,48
Adherence to dietary advice among intervention groups has pre-
viously been reported to be low, with around a third of participants 
in the EAT study adherent as per protocol.49 The tension between 
efficacy (does the intervention work under ideal circumstances) and 
effectiveness (does the intervention work in real life) needs to be 
carefully considered in the design of any follow-on trial.
4.4  |  Research and practice
In the absence of any symptom constellations suggestive of food 
allergy, clinicians should continue to focus on positively promoting 
a “control, not cure” message when communicating with parents 
about childhood eczema. For the majority, this means supporting 
parents to moisturize their child's skin regularly and use topical corti-
costeroids of an appropriate strength and duration according to the 
site and severity of their child's eczema.
The importance of this topic, lack of research in this area and 
our study's findings support the need for, and feasibility of, a defini-
tive trial of food allergy screening in children with eczema. Because 
of the uncertainty around the diagnosis in primary care, we favour 
not asking FPs in any future trial to pre-screen potential invitees 
for suspected food allergy. We also think the emphasis should be 
on recruiting infants when complementary feeding starts and new 
foods are eaten for the first time; and on foods which are regu-
larly consumed and may therefore be more likely to causes eczema 
symptoms, such as cow's milk, egg or wheat. It is important to recruit 
from as diverse socio-economic and ethnic backgrounds as possi-
ble. Ways to achieve this may be through recruiting incident (rather 
than prevalent) cases of eczema and to concentrate recruitment in 
more deprived and ethnically diverse areas. Intervention design and 
delivery should probably sit on the pragmatic side of the efficacy/
effectiveness divide, but investigators must be mindful of possible 
effects of delayed introduction or exclusion of foods on immune 
tolerance. Similarly, careful consideration must be made to any po-
tential trade-off between dietary restrictions that might improve 
eczema symptoms but may impair other aspects of quality of life 
because of restricted dietary choices for the child and family.
ACKNOWLEDG EMENTS
This study was designed and is being delivered in collaboration with 
the Bristol Randomised Trials Collaboration (BRTC), a UKCRC regis-
tered clinical trials unit which, as part of the Bristol Trials Centre, is in 
receipt of National Institute for Health Research CTU support fund-
ing. The study was developed with support from UK Dermatology 
Clinical Trials Network (UK DCTN). The UK DCTN is grateful to 
the British Association of Dermatologists and the University of 
Nottingham for financial support of the Network. Trial steering and 
data monitoring committee members: Professor Carl Heneghan 
(chair), Dr David Gillespie (statistician), Dr Joanne Walsh (FP with 
specialist interest in allergy) and Kate Sykes (parent of child with ec-
zema and food allergy).
CONFLIC T OF INTERE S T
MJR: No financial interests; convenes the NIHR SPCR Allergy 
working group; and was a member of the NICE Quality Standard 
44 for Atopic eczema in under 12 s and RCPCH “Care pathway for 
children with eczema” groups. LW: Direct – financial: writes arti-
cles, participates in infant formula advisory board meetings and 
presents at sponsored lectures relating to food allergy; has re-
ceived infant formula company sponsorship to attend national/in-
ternational allergy-related conferences/ meetings. Runs a private 
practice (Food Allergy Nottingham Service Ltd, 2013-) in addition 
to NHS role (Feb 2012-). BDA cow's milk allergy course facilitator 
(2018-), Dietetic telephone service advisor for Allergy UK (2020-). 
Direct – non-financial: member of RCPCH faculty for tier 3 paedi-
atric allergy course (2018-); member of Allergy UK health advisory 
board (2015-); member of iMAP implementation team (2017-); 
produces food allergy-related dietary information for BDA food 
allergy group (2014-); NICE Expert adviser relating to paediatric 
food allergy and gastro-oesophageal reflux (2017–2020); previous 
member of NICE food allergy guidelines GDG and RCPCH food 
allergy care pathway (2010–2011). RJB has received honoraria for 
participating in advisory boards for ALK-Abello, DBV technologies 
and Prota therapeutics, who research or manufacture treatments 
for people with food allergy.
10  |    RIDD et al.
AUTHOR CONTRIBUTIONS
MJR conceived the study in collaboration with RJB, MS, JRC and IM. 
MJR, RJB, MS, JRC, IM, ARGS, DM, KR, KG, PSB and JK developed the 
initial study design, with later input from JC, LS, LW, EA and JT. Specific 
advice was given by PSB and NLT on trial design and medical statistics; 
ARGS, LS and CC on the nested qualitative study; and KG and JC on 
the economic scoping. All the authors contributed to the drafting of 
the study protocol, led by MJR and approved the final manuscript.
DATA AVAIL ABILIT Y S TATEMENT
No later than 3 years after the completion of the study, we will make 
available a completely de-identified data set to an appropriate data 
archive for sharing purposes.
ORCID
Matthew J. Ridd  https://orcid.org/0000-0002-7954-8823 
Anna Gilbertson  https://orcid.org/0000-0003-3946-9132 
Robert J. Boyle  https://orcid.org/0000-0002-4913-7580 
R E FE R E N C E S
 1. Johansson S, Bieber T, Dahl R, et al. Revised nomenclature for al-
lergy for global use: Report of the Nomenclature Review Committee 
of the World Allergy Organization, October 2003. J Allergy Clin 
Immunol. 2004;113:832-836.
 2. NICE. CG057: Atopic Eczema in Children - Management of Atopic 
Eczema in Children from Birth up to the Age of 12 years. London: 
RCOG Press, 2007. https://www.nice.org.uk/guida nce/cg57/resou 
rces/atopi c-eczem a-in-under -12s-diagn osis-and-manag ement -pdf-
97551 2529349
 3. Martin PE, Eckert JK, Koplin JJ, et al. Which infants with eczema 
are at risk of food allergy? Results from a population-based co-
hort. Clin Exp Allergy. 2015;45(1):255-264. https://doi.org/10.1111/
cea.12406
 4. Santer M, Burgess H, Yardley L, et al. Experiences of carers man-
aging childhood eczema and their views on its treatment: a qual-
itative study. Br J Gen Pract. 2012;62(597):e261-e267. https://doi.
org/10.3399/bjgp1 2X636083
 5. Powell K, Le Roux E, Banks J, et al. GP and parent dissonance about 
the assessment and treatment of childhood eczema in primary 
care: a qualitative study. BMJ Open. 2018;8(2):e019633. https://
doi.org/10.1136/bmjop en-2017-019633
 6. Khanna R, Shifrin N, Nektalova T, et al. Diet and dermatology: 
google search results for acne, psoriasis, and eczema. Cutis. 
2018;102:44-46.
 7. Halls A, Nunes D, Muller I, et al. ‘Hope you find your ‘eu-
reka’ moment soon’: a qualitative study of parents/carers’ on-
line discussions around allergy, allergy tests and eczema. BMJ 
Open. 2018;8(11):e022861. https://doi.org/10.1136/bmjop 
en-2018-022861
 8. Chan JP, Ridd MJ. Carer and patient beliefs and practices regard-
ing the role of food allergy in eczema: cross-sectional survey. 
Clin Exp Dermatol. 2019;44:e235-e237. https://doi.org/10.1111/
ced.13955
 9. Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common 
food allergies in Europe: a systematic review and meta-analysis. 
Allergy. 2014;69(8):992-1007. https://doi.org/10.1111/all.12423
 10. Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of 
food allergy in school-aged children in eight European countries—
The EuroPrevall-iFAAM birth cohort. Allergy. 2020;75(9):2294-
2308. https://doi.org/10.1111/all.14290
 11. Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermati-
tis cause food allergy? A systematic review. J Allergy Clin 
Immunol. 2016;137(4):1071-1078. https://doi.org/10.1016/j.
jaci.2015.10.049
 12. Sova C, Feuling MB, Baumler M, et al. Systematic review of nu-
trient intake and growth in children with multiple IgE-mediated 
food allergies. Nutr Clin Pract. 2013;28(6):669-675. https://doi.
org/10.1177/08845 33613 505870
 13. Meyer R. Nutritional disorders resulting from food allergy in chil-
dren. Pediatr Allergy Immunol. 2018;29(7):689-704. https://doi.
org/10.1111/pai.12960
 14. Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for 
improving established atopic eczema in adults and children: sys-
tematic review. Allergy. 2009;64(2):258-264.
 15. de Silva D, Halken S, Singh C, et al. Preventing food allergy in in-
fancy and childhood: systematic review of randomised controlled 
trials. Pediatr Allergy Immunol. 2020;31(7):813-826. https://doi.
org/10.1111/pai.13273
 16. Ierodiakonou D, Garcia-Larsen V, Logan A, et al. Timing of 
allergenic food introduction to the infant diet and risk of 
allergic or autoimmune disease: a systematic review and meta-anal-
ysis. JAMA. 2016;316(11):1181-1192. https://doi.org/10.1001/
jama.2016.12623
 17. Lever R, MacDonald C, Waugh P, et al. Randomised controlled 
trial of advice on an egg exclusion diet in young children with 
atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol. 
1998;9(1):13-19. https://doi.org/10.1111/j.1399-3038.1998.
tb002 94.x
 18. Nankervis H, Thomas K, Delamere F, et al. Scoping systematic 
review of treatments for eczema. Programme Grants Appl Res. 
2016;4(7):1-480.
 19. Chafen JJS, Newberry SJ, Riedl MA, et al. Diagnosing and 
managing common food allergies: a systematic review. 
JAMA. 2010;303(18):1848-1856. https://doi.org/10.1001/
jama.2010.582
 20. Ridd MJ, Edwards L, Santer M, et al. TEST (Trial of Eczema al-
lergy Screening Tests): protocol for feasibility randomised 
controlled trial of allergy tests in children with eczema, in-
cluding economic scoping and nested qualitative study. BMJ 
Open. 2019;9(5):e028428. https://doi.org/10.1136/bmjop 
en-2018-028428
 21. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema 
measure: development and initial validation of a new tool for mea-
suring atopic eczema severity from the patients’ perspective. Arch 
Dermatol. 2004;140(12):1513-1519.
 22. Charman C, Venn A, Ravenscroft J, et al. Translating Patient-
Oriented Eczema Measure (POEM) scores into clinical practice by 
suggesting severity strata derived using anchor-based methods. 
Br J Dermatol. 2013;169(6):1326-1332. https://doi.org/10.1111/
bjd.12590
 23. Heinzerling L, Mari A, Bergmann K-C, et al. The skin prick test – 
European standards. Clin Transl Allergy. 2013;3(1):3. https://doi.
org/10.1186/2045-7022-3-3
 24. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, 
et al. Standardizing double-blind, placebo-controlled oral food 
challenges: American Academy of Allergy, Asthma & Immunology - 
European Academy of Allergy and Clinical Immunology PRACTALL 
consensus report. J Allergy Clin Immunol. 2012;130(6):1260-1274. 
https://doi.org/10.1016/j.jaci.2012.10.017
 25. Schmitt J, Spuls P, Boers M, et al. Towards global consensus 
on outcome measures for atopic eczema research: results of 
the HOME II meeting. Allergy. 2012;67:1111-1117. https://doi.
org/10.1111/j.1398-9995.2012.02874.x
 26. Tofte SJ, Graber M, Cherill R, et al. Eczema area and severity index 
(EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol 
Venereol. 1998;11 (Suppl 2):S197.
    |  11RIDD et al.
 27. Stevens KJ, Brazier JE, McKenna SP, et al. The development of a 
preference-based measure of health in children with atopic derma-
titis. Br J Dermatol. 2005;153(2):372-377.
 28. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ dermati-
tis quality of life index. BJD. 2001;144(1):104-110. https://doi.
org/10.1046/j.1365-2133.2001.03960.x
 29. Stevens K. Assessing the performance of a new generic measure of 
health-related quality of life for children and refining it for use in 
health state valuation. Appl Health Econ Health Policy. 2011;9(3):157-
169. https://doi.org/10.2165/11587 350-00000 0000-00000
 30. Malterud K, Siersma VD, Guassora AD. Sample size in qualitative 
interview studies: guided by information power. Qual Health Res. 
2016;26(13):1753-1760. https://doi.org/10.1177/10497 32315 
617444
 31. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic 
analysis: a hybrid approach of inductive and deductive coding and 
theme development. Int J Qual Methods. 2006;5(1):80-92. https://
doi.org/10.1177/16094 06906 00500107
 32. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res 
Psychol. 2006;3(2):77-101. https://doi.org/10.1191/14780 88706 
qp063oa
 33. Clement C, Ridd MJ, Roberts K, et al. Parents and GPs’ under-
standings and beliefs about food allergy testing in children 
with eczema: qualitative interview study within the Trial of 
Eczema allergy Screening Tests (TEST) feasibility trial. BMJ Open. 
2020;10(11):e041229.
 34. Batchelor JM, Ridd MJ, Clarke T, et al. The Eczema Priority Setting 
Partnership: a collaboration between patients, carers, clinicians 
and researchers to identify and prioritize important research ques-
tions for the treatment of eczema. Br J Dermatol. 2013;168(3):577-
582. https://doi.org/10.1111/bjd.12040
 35. Williams HC, Jburney PG, Hay RJ, et al. The U.K. Working 
Party's diagnostic criteria for atopic dermatitis. Br J Dermatol. 
1994;131(3):383-396.
 36. Chalmers JR, Haines RH, Mitchell EJ, et al. Effectiveness and 
cost-effectiveness of daily all-over-body application of emol-
lient during the first year of life for preventing atopic eczema in 
high-risk children (The BEEP trial): protocol for a randomised con-
trolled trial. Trials. 2017;18(1):343. https://doi.org/10.1186/s1306 
3-017-2031-3
 37. Ridd MJ, Wells S, Edwards L, et al. Best emollients for eczema 
(BEE) – comparing four types of emollients in children with ec-
zema: protocol for randomised trial and nested qualitative study. 
BMJ Open. 2019;9(11):e033387. https://doi.org/10.1136/bmjop 
en-2019-033387
 38. Ridd MJ, Garfield K, Gaunt DM, et al. Choice of Moisturiser for 
Eczema Treatment (COMET): feasibility study of a randomised con-
trolled parallel group trial in children recruited from primary care. 
BMJ Open. 2016;6(11):e012021. https://doi.org/10.1136/bmjop 
en-2016-012021
 39. Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during 
infancy for prevention of eczema: the BEEP randomised controlled 
trial. Lancet. 2020;395(10228):962-972. https://doi.org/10.1016/
S0140 -6736(19)32984 -8
 40. Santer M, Ridd MJ, Francis NA, et al. Emollient bath additives for 
the treatment of childhood eczema (BATHE): multicentre pragmatic 
parallel group randomised controlled trial of clinical and cost ef-
fectiveness. BMJ. 2018;361:k1332. https://doi.org/10.1136/bmj.
k1332
 41. Jacquet L, Gaunt DM, Garfield K, et al. Diagnosis, assessment, and 
treatment of childhood eczema in primary care: cross-sectional 
study. BJGP Open. 2017;1(2). https://doi.org/10.3399/bjgpo pen17 
X100821
 42. Sicherer SH, Sampson HA. Food allergy: a review and update on 
epidemiology, pathogenesis, diagnosis, prevention, and man-
agement. J Allergy Clin Immunol. 2018;141(1):41-58. https://doi.
org/10.1016/j.jaci.2017.11.003.
 43. Gore C, Johnson RJ, Caress AL, et al. The information needs and 
preferred roles in treatment decision-making of parents car-
ing for infants with atopic dermatitis: a qualitative study. Allergy. 
2005;60:938-943.
 44. Flohr C, Mann J. New insights into the epidemiology of childhood 
atopic dermatitis. Allergy. 2014;69(1):3-16. https://doi.org/10.1111/
all.12270
 45. Luyt D, Ball H, Kirk K, et al. Diagnosis and management of food al-
lergy in children. Paediatr Child Health. 2016;26(7):287-291. https://
doi.org/10.1016/j.paed.2016.02.005
 46. Sicherer SH, Sampson HA. Food hypersensitivity and atopic der-
matitis: pathophysiology, epidemiology, diagnosis, and manage-
ment. J Allergy Clin Immunol. 1999;104(3):S114-S122. https://doi.
org/10.1016/S0091 -6749(99)70053 -9
 47. Hill DJ, Sporik R, Thorburn J, et al. The association of atopic derma-
titis in infancy with immunoglobulin E food sensitization. J Pediatr. 
2000;137(4):475-479. https://doi.org/10.1067/mpd.2000.108207
 48. Hill DJ, Hosking CS. Food allergy and atopic dermatitis in infancy: 
an epidemiologic study. Pediatr Allergy Immunol. 2004;15(5):421. 
https://doi.org/10.1111/j.1399-3038.2004.00178.x
 49. Perkin MR, Logan K, Tseng A, et al. Randomized trial of intro-
duction of allergenic foods in breast-fed infants. New Engl J 
Med. 2016;374(18):1733-1743. https://doi.org/10.1056/NEJMo 
a1514210
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Ridd MJ, Webb D, Roberts K, et al. 
Test-guided dietary management of eczema in children: A 
randomized controlled feasibility trial (TEST). Clin Exp Allergy. 
2021;00:1–11. https://doi.org/10.1111/cea.13816
